Loading
Pharmacogenomics studies how a person's genes, and a tumour's genes, change the way drugs work or cause harm.
Pharmacogenomics, abbreviated PGx, is the study of the role of the genome in drug response, combining pharmacology and genomics to ask how a patient's genetic makeup affects their reaction to drugs (Wikipedia). In oncology it covers both inherited variants that govern toxicity (DPYD and fluoropyrimidines, TPMT and thiopurines) and the tumour's somatic alterations that predict sensitivity, the basis of cell-line drug-response prediction.
Showing the technology this term belongs to: Pharmacogenomic testing before chemotherapy.
Shares Drug response and drug sensitivity (IC50, AUC), Cancer AI vocabulary (CanSim terms map) and the tag cansim-terms.
Shares Actionable genomic biomarkers, Cancer AI vocabulary (CanSim terms map) and the tag cansim-terms.
Shares Drug response and drug sensitivity (IC50, AUC), Cancer AI vocabulary (CanSim terms map) and the tag cansim-terms.
Shares Cancer AI vocabulary (CanSim terms map) and the tag cansim-terms.
Shares Cancer AI vocabulary (CanSim terms map) and the tag cansim-terms.
Shares Cancer AI vocabulary (CanSim terms map) and the tag cansim-terms.
Shares Cancer AI vocabulary (CanSim terms map) and the tag cansim-terms.
Shares Cancer AI vocabulary (CanSim terms map) and the tag cansim-terms.